Paracetamol Effect on Oxidative Stress and Renal Function in Severe Malaria
NCT01641289 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 62
Last updated 2018-06-14
Summary
Blackwater fever, characterized by intravascular haemolysis and hemoglobinuria, is an important cause of renal impairment and mortality in severe malaria caused by Plasmodium falciparum. The largest malaria clinical trials report blackwater incidences of 5-7% in Asian adults and 4% in African children with severe malaria treated with artesunate or quinine. The prevalence of blackwater fever in Chittagong, Bangladesh is 15% with associated rates of renal failure and mortality of 42.9% and 14.2% respectively.
The fundamental characteristic of blackwater fever is the presence of intravascular hemolysis of both infected and uninfected erythrocytes and release of free haemoglobin. The cytotoxic free haemoglobin present can cause severe oxidative damage as a result of haem redox cycling yielding ferric and ferryl heme, which generate radical species that induce lipid peroxidation and subsequent production of F2-isoprostanes (F2-IsoPs). Evidence suggests that F2-IsoPs generated by the hemoprotein-catalyzed oxidation of lipids are responsible for the oxidative damage and vasoconstriction associated with renal injury in haemolytic disorders and rhabdomyolysis.
A novel mechanism of paracetamol was recently demonstrated, showing that paracetamol is a potent inhibitor of hemoprotein-catalyzed lipid peroxidation by reducing ferryl heme to its less toxic ferric state and quenching globin radicals. In a recent proof of concept trial, paracetamol at therapeutic levels was shown to significantly decrease oxidant kidney injury, improve renal function and reduce renal damage by inhibiting the hemoprotein-catalyzed lipid peroxidation in a rat model of rhabdomyolysis-induced renal injury. Since adults with severe malaria demonstrate increased concentrations of cell-free haemoglobin, and urinary F2-IsoPs, the investigators hypothesize that this novel inhibitory mechanism of paracetamol may provide renal protection in this population by reducing the hemoprotein-induced lipid peroxidation. As there is currently no consensus that exists concerning adequate medical treatment for blackwater fever, the potential application of this safe and extensively used drug would be of great benefit.
Conditions
Interventions
- DRUG
-
\>50kg: Paracetamol 1gm PO/NG q6hourly for 72hours and afebrile for 24h (maximum total dose 4g/24 hours) plus intravenous Artesunate \<50kg: Paracetamol 12.5-15mg/kg/dose q6hourly for 72hours and afebrile for 24h (maximum total dose 5 doses/24hours;75mg/kg) plus intravenous Artesunate
- DRUG
-
No Paracetamol
No paracetamol + Intravenous Artesunate * If temperature \> 40°C, ibuprofen PO/PR will be administered in the absence of renal impairment and dehydration; 500mg paracetamol PO/PR will be administered in the presence of renal impairment or dehydration. Dengue testing will be done prior to the administration of ibuprofen.
Sponsors & Collaborators
-
University of Oxford
lead OTHER
Principal Investigators
-
Katherine Plewes, MD · University of Oxford
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 12 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2012-07-10
- Primary Completion
- 2014-09-13
- Completion
- 2014-09-21
Countries
- Bangladesh
Study Locations
More Related Trials
-
Severe and Cerebral Malaria Investigated Through Host Metabolomics
NCT02451904 ·Status: COMPLETED
-
Clinical Evaluation of Long-term Sequelae in Patients With Severe Plasmodium Falciparum Malaria
NCT06992297 ·Status: COMPLETED ·Phase: NA
-
Delivery of Malaria Chemoprevention in the Post-discharge Management of Children With Severe Anaemia in Malawi
NCT02721420 ·Status: UNKNOWN ·Phase: PHASE3
-
Treatment of Malaria With Quinine Plus Sulfadoxine-Pyrimethamine
NCT00167739 ·Status: COMPLETED ·Phase: PHASE4
-
Intermittent Preventive Treatment (IPTi) for the Prevention of Malaria and Anaemia in PNG Infants
NCT00285662 ·Status: COMPLETED ·Phase: NA
-
Child Follow-up Until 2 Years
NCT02800109 ·Status: COMPLETED
-
Aggressive Antipyretics for Fever Reduction in CNS Malaria
NCT03399318 ·Status: COMPLETED ·Phase: PHASE2
-
Impact of Malaria on Pregnant Women in Ouelessebougou, Mali
NCT02974608 ·Status: COMPLETED
-
Determining a Tolerable Dose of Primaquine in G6PD-deficient Persons Without Malaria in Mali
NCT02535767 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Role of Nitric Oxide in Malaria
NCT00527163 ·Status: COMPLETED
-
Study to Assess the Incidence of Hemolysis, Safety, and Efficacy of Tafenoquine (SB-252263, WR238605) Versus Primaquine in Subjects With Plasmodium Vivax Malaria
NCT02216123 ·Status: COMPLETED ·Phase: PHASE3
-
DON in Pediatric Cerebral Malaria
NCT05478720 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
An MRI Ancillary Study of a Malaria Fever Investigation
NCT05746819 ·Status: COMPLETED
-
Host and Parasite Factors That Influence Susceptibility to Malaria Infection and Disease During Pregnancy and Early Childhood in Ouelessebougou and Bamako, Mali
NCT01168271 ·Status: RECRUITING
-
CQSP in Malawi: Chloroquine and Sulfadoxine-pyrimethamine Efficacy for the Treatment of Malaria in Malawi
NCT00125489 ·Status: COMPLETED ·Phase: PHASE4
-
Intermittent Preventive Treatment for Malaria in Patient With Sickle Cell Disease
NCT01319448 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Community-based Screening and Treatment of Malaria in Pregnancy: a Cluster-randomized Trial
NCT01941264 ·Status: COMPLETED ·Phase: NA
-
PALUREA: Severe Imported Malaria in Adults
NCT00372684 ·Status: COMPLETED
-
Control of Pregnancy Associated Malaria With Intermittent Preventive Treatment
NCT00258024 ·Status: COMPLETED ·Phase: NA
-
Hyperphenylalaninemia in Cerebral Malaria
NCT00338520 ·Status: COMPLETED
-
Efficacy of Amodiaquine in the Treatment of Uncomplicated Falciparum Malaria in Young Children of Burkina Faso
NCT00261222 ·Status: COMPLETED ·Phase: PHASE2
-
Dihydroartemisinin-Piperaquine or Sulphadoxine-Pyrimethamine for the Chemoprevention of Malaria in Sickle Cell Anaemia
NCT04844099 ·Status: COMPLETED ·Phase: PHASE3
-
Evaluation of Rapid Diagnosis Tests in Imported Malaria
NCT00451269 ·Status: COMPLETED
-
Post-discharge Malaria Chemoprevention(PMC) Study
NCT02671175 ·Status: COMPLETED ·Phase: PHASE3
-
Study of Iron Absorption and Utilization in Asymptomatic Malaria
NCT01108939 ·Status: COMPLETED ·Phase: EARLY_PHASE1